LOGIN  |  REGISTER
Recursion

List of Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 135.62
-0.83 -0.61
3.22M
1.73B
US$ 234.620B
US$ 511.82
-1.18 -0.23
1.95M
356.18M
US$ 182.300B
US$ 402.76
-12.57 -3.03
2.33M
382.50M
US$ 154.060B
US$ 99.74
1.18 1.20
8.49M
1.47B
US$ 146.620B
US$ 200.67
-4.43 -2.16
3.25M
722.28M
US$ 144.940B
US$ 377.30
-3.19 -0.84
818,509
381.22M
US$ 143.830B
US$ 87.27
-1.22 -1.38
5.80M
1.28B
US$ 111.710B
US$ 728.20
-2.60 -0.36
485,932
126.94M
US$ 92.440B
US$ 172.21
-2.25 -1.29
2.20M
290.01M
US$ 49.940B
US$ 75.15
-0.74 -0.98
2.57M
589.80M
US$ 44.320B
US$ 522.70
-4.22 -0.80
385,155
81.88M
US$ 42.800B
US$ 86.20
-2.92 -3.28
1.64M
494.60M
US$ 42.630B
US$ 161.41
0.89 0.55
2.24M
242.01M
US$ 39.060B
US$ 249.34
-2.87 -1.14
404,091
146.80M
US$ 36.600B
US$ 117.08
-1.83 -1.54
1.60M
285.60M
US$ 33.440B
US$ 81.99
-0.86 -1.04
2.78M
390.60M
US$ 32.030B
US$ 156.89
-2.24 -1.41
1.40M
181.50M
US$ 28.480B
US$ 1.00
-32.79 -2.76
106,536
21.10M
US$ 24.380B
US$ 241.34
-1.07 -0.44
440,962
98.71M
US$ 23.820B
US$ 261.12
-0.53 -0.20
546,815
83.64M
US$ 21.840B
US$ 165.34
0.99 0.60
699,973
132.02M
US$ 21.830B
US$ 304.63
1.01 0.33
649,522
70.14M
US$ 21.370B
US$ 342.30
-7.15 -2.05
320,601
59.38M
US$ 20.330B
US$ 180.21
1.17 0.65
1.01M
111.62M
US$ 20.120B
US$ 91.28
-1.98 -2.12
1.33M
199.07M
US$ 18.170B
US$ 221.91
-3.00 -1.33
508,487
72.42M
US$ 16.070B
US$ 30.62
-0.74 -2.36
2.82M
510.59M
US$ 15.630B
US$ 64.75
-0.47 -0.72
2.21M
225.72M
US$ 14.620B
US$ 69.70
-1.18 -1.66
1.55M
199.58M
US$ 13.910B
US$ 86.93
-1.20 -1.36
1.56M
158.60M
US$ 13.790B
US$ 29.39
-0.71 -2.36
833,167
435.99M
US$ 12.810B
US$ 145.66
-1.39 -0.95
1.28M
82.56M
US$ 12.030B
US$ 93.53
-2.17 -2.27
649,777
121.70M
US$ 11.380B
US$ 71.28
0.05 0.07
12.64M
152.40M
US$ 10.860B
US$ 47.11
-0.28 -0.59
1.06M
222.26M
US$ 10.470B
US$ 53.52
-0.49 -0.91
1.23M
185.08M
US$ 9.910B
US$ 256.50
3.10 1.22
361,721
38.38M
US$ 9.840B
US$ 298.25
-5.75 -1.89
323,093
31.08M
US$ 9.270B
US$ 161.20
-4.14 -2.50
537,612
53.54M
US$ 8.630B
US$ 149.45
-2.44 -1.61
635,216
51.14M
US$ 7.640B
US$ 127.52
-3.78 -2.88
498,888
56.03M
US$ 7.140B
US$ 58.90
-1.30 -2.16
1.12M
113.74M
US$ 6.700B
US$ 49.29
0.27 0.55
1.88M
123.56M
US$ 6.090B
US$ 38.30
-1.57 -3.94
1.58M
151.60M
US$ 5.810B
US$ 119.93
-2.17 -1.78
361,430
46.44M
US$ 5.570B
US$ 92.97
-0.61 -0.65
601,059
58.28M
US$ 5.420B
US$ 77.83
-2.31 -2.88
1.96M
69.53M
US$ 5.410B
US$ 97.60
-0.02 -0.02
783,545
55.14M
US$ 5.380B
US$ 226.91
-5.51 -2.37
444,109
22.92M
US$ 5.200B
US$ 142.88
-0.16 -0.11
846,842
33.56M
US$ 4.800B
US$ 79.97
0.00 0.00
0
58.56M
US$ 4.680B
US$ 143.85
-1.63 -1.12
307,506
31.30M
US$ 4.500B
US$ 12.33
-0.11 -0.88
1.37M
352.16M
US$ 4.340B
US$ 83.97
-1.17 -1.37
212,050
49.41M
US$ 4.150B
US$ 55.41
-1.17 -2.07
684,381
74.03M
US$ 4.100B
US$ 118.30
-0.45 -0.38
363,382
33.54M
US$ 3.970B
US$ 127.18
-1.49 -1.16
972,925
29.97M
US$ 3.810B
US$ 70.98
0.00 0.00
0
51.11M
US$ 3.630B
US$ 70.09
-1.27 -1.78
278,180
50.22M
US$ 3.520B
US$ 60.63
-0.53 -0.87
522,136
54.11M
US$ 3.280B
US$ 11.43
-0.32 -2.72
1.98M
283.24M
US$ 3.240B
US$ 132.04
-0.31 -0.23
183,946
24.48M
US$ 3.230B
US$ 45.76
-0.87 -1.87
401,978
54.30M
US$ 2.480B
US$ 22.73
0.26 1.16
2.43M
101.66M
US$ 2.310B
US$ 33.52
-0.11 -0.33
646,442
59.58M
US$ 2.000B
US$ 28.90
-0.98 -3.28
1.57M
67.26M
US$ 1.940B
US$ 17.55
-0.65 -3.57
1.30M
108.20M
US$ 1.900B
US$ 81.13
-0.24 -0.29
221,039
22.48M
US$ 1.820B
US$ 53.55
-1.41 -2.57
316,745
30.89M
US$ 1.650B
US$ 11.06
-0.31 -2.73
1.97M
141.77M
US$ 1.570B
US$ 31.62
-0.71 -2.20
607,716
48.75M
US$ 1.540B
US$ 30.60
0.19 0.62
656,364
45.69M
US$ 1.400B
US$ 41.31
-0.61 -1.46
744,644
33.60M
US$ 1.390B
US$ 20.76
-0.16 -0.76
1.94M
65.68M
US$ 1.360B
US$ 5.53
-0.09 -1.60
7.45M
216.94M
US$ 1.200B
US$ 28.25
-0.47 -1.64
225,081
41.92M
US$ 1.180B
US$ 8.60
-0.20 -2.27
862,208
134.56M
US$ 1.160B
US$ 23.48
-0.52 -2.17
466,068
49.60M
US$ 1.160B
US$ 13.09
0.00 0.00
0
83.72M
US$ 1.100B
US$ 37.44
0.32 0.86
654,501
28.76M
US$ 1.080B
US$ 19.96
-0.32 -1.58
335,669
52.94M
US$ 1.060B
US$ 13.36
-0.69 -4.91
2.36M
76.25M
US$ 1.020B
US$ 22.03
-1.27 -5.45
732,896
46.39M
US$ 1.020B
US$ 18.59
-0.24 -1.27
559,508
53.63M
US$ 996.980M
US$ 15.77
-0.41 -2.53
171,104
61.52M
US$ 970.170M
US$ 12.16
-0.53 -4.18
924,417
77.16M
US$ 938.270M
US$ 7.07
-0.32 -4.33
2.84M
128.36M
US$ 907.510M
US$ 1.33
-0.01 -0.75
2.33M
672.80M
US$ 894.820M
US$ 6.04
-0.08 -1.31
919,584
146.95M
US$ 887.580M
US$ 17.08
-0.35 -2.01
1.07M
49.28M
US$ 841.700M
US$ 58.17
-1.39 -2.33
37,361
12.67M
US$ 737.010M
US$ 17.42
-0.84 -4.60
1.55M
41.94M
US$ 730.590M
US$ 20.69
-0.30 -1.43
193,575
30.59M
US$ 632.910M
US$ 17.27
-0.90 -4.95
768,993
35.82M
US$ 618.610M
US$ 7.79
-0.18 -2.26
804,572
77.11M
US$ 600.690M
US$ 14.21
-0.06 -0.42
955,861
40.30M
US$ 572.660M
US$ 12.10
-0.27 -2.18
271,954
45.96M
US$ 556.120M
US$ 15.34
-0.30 -1.92
314,787
36.20M
US$ 555.310M
US$ 18.75
-0.07 -0.37
508,181
28.01M
US$ 525.190M
US$ 21.16
-0.56 -2.58
107,591
24.22M
US$ 512.500M
US$ 3.65
-0.05 -1.35
53,714
139.82M
US$ 510.340M
US$ 5.03
-0.16 -3.08
1.27M
91.04M
US$ 457.930M
US$ 6.62
-0.09 -1.34
248,713
65.37M
US$ 432.750M
US$ 10.66
-0.23 -2.11
669,795
40.47M
US$ 431.410M
US$ 2.30
-0.14 -5.74
7.11M
186.64M
US$ 429.270M
US$ 9.75
-0.29 -2.89
549,817
44.01M
US$ 429.100M
US$ 11.00
-0.16 -1.43
345,265
38.21M
US$ 420.310M
US$ 29.16
0.08 0.28
78,282
14.29M
US$ 416.700M
US$ 3.22
-0.14 -4.17
1.48M
128.81M
US$ 414.770M
US$ 4.39
-0.13 -2.88
2.70M
92.44M
US$ 405.810M
US$ 1.05
0.00 0.00
897,397
372.26M
US$ 390.870M
US$ 16.04
-0.04 -0.25
102,554
23.48M
US$ 376.620M
US$ 5.67
-0.20 -3.41
388,355
62.30M
US$ 353.240M
US$ 1.20
0.02 1.69
6.95M
294.32M
US$ 353.180M
C$ 2.24
0.00 0.00
0
154.17M
C$ 345.340M
US$ 8.19
-0.33 -3.87
412,839
41.23M
US$ 337.670M
US$ 11.07
-0.16 -1.42
502,026
29.85M
US$ 330.440M
US$ 0.51
-0.009 -1.73
15.28M
595.33M
US$ 304.210M
US$ 6.06
-0.13 -2.10
1.08M
49.57M
US$ 300.390M
US$ 5.04
-0.12 -2.33
842,715
58.52M
US$ 294.940M
US$ 7.54
-0.02 -0.26
21,035
37.43M
US$ 282.220M
US$ 29.58
-1.16 -3.77
643,678
9.27M
US$ 274.210M
US$ 6.65
-0.13 -1.92
99,322
38.94M
US$ 258.950M
US$ 4.68
-0.40 -7.79
41,814
55.19M
US$ 258.010M
US$ 7.31
0.12 1.67
344,352
34.82M
US$ 254.530M
US$ 28.81
0.12 0.42
55,754
8.74M
US$ 251.800M
US$ 9.10
-0.20 -2.15
198,761
27.60M
US$ 251.160M
C$ 0.88
0.00 0.00
71,200
282.82M
C$ 248.880M
US$ 28.00
0.00 0.00
0
8.53M
US$ 238.840M
US$ 9.84
-0.11 -1.11
270,577
24.00M
US$ 236.160M
US$ 2.20
-0.07 -3.08
910,856
105.48M
US$ 232.060M
US$ 1.66
-0.13 -7.26
7.99M
138.40M
US$ 229.740M
US$ 2.95
0.02 0.68
837,562
74.59M
US$ 220.040M
US$ 5.84
0.00 0.00
0
37.47M
US$ 218.820M
US$ 3.17
-0.05 -1.55
2.63M
67.59M
US$ 214.260M
US$ 3.79
-0.02 -0.52
296,852
55.65M
US$ 210.910M
US$ 4.13
-0.08 -1.90
161,247
50.40M
US$ 208.150M
US$ 10.90
-0.52 -4.55
39,357
18.82M
US$ 205.140M
US$ 6.54
0.21 3.32
28,301
30.03M
US$ 196.400M
US$ 55.16
-2.20 -3.84
77,136
3.39M
US$ 186.990M
US$ 2.11
-0.06 -2.76
796,578
84.73M
US$ 178.780M
US$ 20.07
-0.02 -0.10
132,416
8.46M
US$ 169.790M
US$ 5.19
-0.31 -5.64
29,564
30.49M
US$ 158.240M
US$ 4.38
-0.49 -10.06
215,464
35.94M
US$ 157.420M
US$ 6.25
-0.19 -2.95
129,048
23.82M
US$ 148.880M
US$ 3.23
0.03 0.94
95,036
45.84M
US$ 148.060M
US$ 12.51
0.01 0.08
55,606
11.61M
US$ 145.240M
US$ 5.51
-0.29 -5.00
580,729
26.22M
US$ 144.470M
US$ 5.86
-0.07 -1.18
282,636
24.26M
US$ 142.160M
US$ 3.55
-0.06 -1.66
88,476
37.72M
US$ 133.910M
US$ 6.21
0.11 1.80
210,758
21.26M
US$ 132.020M
US$ 39.56
-1.36 -3.32
25,423
3.26M
US$ 128.970M
US$ 7.12
0.14 2.01
379,510
17.64M
US$ 125.600M
US$ 1.22
-0.03 -2.40
817,149
100.56M
US$ 122.680M
US$ 3.03
-0.10 -3.19
178,449
39.49M
US$ 119.650M
US$ 7.08
0.61 9.43
360,337
16.04M
US$ 113.560M
US$ 0.68
-0.01 -1.74
37,882
156.55M
US$ 106.920M
US$ 2.01
-0.13 -5.93
360,684
49.50M
US$ 99.640M
US$ 2.80
0.02 0.72
2.32M
33.70M
US$ 94.360M
US$ 2.66
0.03 1.14
63,567
34.31M
US$ 91.260M
US$ 14.55
0.18 1.25
5,109
6.27M
US$ 91.230M
US$ 0.64
-0.02 -2.31
21,917
139.01M
US$ 88.270M
US$ 2.00
-0.05 -2.44
227,741
43.09M
US$ 86.180M
US$ 3.84
-0.03 -0.78
32,709
22.00M
US$ 84.480M
US$ 4.81
-0.16 -3.22
45,943
16.39M
US$ 78.840M
US$ 1.29
-0.02 -1.53
745,167
59.34M
US$ 76.550M
US$ 4.35
-0.04 -0.91
76,292
17.54M
US$ 76.300M
US$ 7.03
-1.18 -14.37
103,486
10.64M
US$ 74.800M
US$ 2.22
-0.13 -5.53
543,738
32.02M
US$ 71.080M
US$ 0.88
-0.01 -1.13
107,811
77.89M
US$ 68.540M
US$ 1.15
-0.04 -3.36
87,535
59.23M
US$ 68.110M
US$ 1.70
-0.15 -8.11
288,282
39.39M
US$ 66.960M
US$ 2.10
0.03 1.45
98,824
31.85M
US$ 66.890M
US$ 1.09
0.02 1.87
74,546
60.93M
US$ 66.410M
US$ 2.36
-0.12 -4.84
1.25M
28.03M
US$ 66.150M
US$ 1.75
0.03 1.74
44,694
37.64M
US$ 65.870M
US$ 2.19
-0.01 -0.45
4,983
29.25M
US$ 64.060M
US$ 1.72
-0.05 -2.60
35,167
37.10M
US$ 63.960M
C$ 0.56
0.01 1.82
72,000
113.40M
C$ 63.500M
US$ 3.50
0.00 0.00
0
17.86M
US$ 62.510M
US$ 0.64
0.04 6.71
2.24M
95.97M
US$ 61.040M
US$ 1.23
-0.03 -2.38
80,118
49.57M
US$ 60.970M
US$ 2.32
-0.18 -7.20
150,837
26.08M
US$ 60.510M
US$ 3.20
-0.12 -3.61
111,783
18.34M
US$ 58.690M
US$ 1.71
-0.07 -3.93
402,627
32.80M
US$ 56.090M
US$ 0.97
-0.02 -1.82
450,136
56.57M
US$ 54.990M
US$ 1.78
-0.11 -5.82
11,126
30.25M
US$ 53.840M
US$ 20.01
0.00 0.00
0
2.54M
US$ 50.830M
US$ 0.12
-0.0027 -2.26
155,066
417.59M
US$ 48.860M
C$ 0.20
0.02 8.33
594,952
247.78M
C$ 48.320M
C$ 0.39
0.005 1.32
43,378
119.77M
C$ 46.110M
US$ 4.40
-0.56 -11.29
86
10.07M
US$ 44.310M
US$ 0.30
-0.0039 -1.30
780,498
145.47M
US$ 43.060M
US$ 0.72
-0.02 -2.59
576,456
57.89M
US$ 41.800M
US$ 7.92
-0.78 -8.97
9,230
5.25M
US$ 41.580M
US$ 1.97
-0.16 -7.51
459,822
20.75M
US$ 40.880M
US$ 3.87
-0.14 -3.49
59,944
10.54M
US$ 40.790M
US$ 1.51
-0.02 -1.31
116,189
26.67M
US$ 40.270M
US$ 5.09
-0.29 -5.39
67,783
6.55M
US$ 33.340M
US$ 3.83
-0.20 -4.96
86,205
8.53M
US$ 32.640M
US$ 3.82
-0.08 -2.05
61,200
8.27M
US$ 31.590M
US$ 2.04
0.00 0.00
0
15.37M
US$ 31.350M
US$ 0.77
-0.03 -3.39
124,698
40.14M
US$ 30.910M
C$ 0.26
0.005 1.96
800
113.10M
C$ 29.410M
C$ 0.32
0.005 1.59
2,500
90.89M
C$ 29.080M
US$ 1.39
-0.05 -3.47
61,352
20.24M
US$ 28.130M
C$ 0.10
0.01 11.76
1.99M
270.17M
C$ 25.670M
US$ 0.67
-0.03 -4.52
270,276
38.39M
US$ 25.570M
US$ 1.76
-0.21 -10.66
71,343
13.96M
US$ 24.570M
C$ 0.31
0.00 0.00
3,500
77.42M
C$ 24.000M
C$ 0.15
0.04 36.36
11.01M
159.67M
C$ 23.950M
US$ 0.51
-0.01 -2.75
1.08M
43.62M
US$ 22.200M
C$ 0.24
0.005 2.17
299,500
93.38M
C$ 21.940M
US$ 0.90
-0.03 -3.03
330,451
22.90M
US$ 20.540M
US$ 0.67
-0.03 -3.82
213,346
29.94M
US$ 19.970M
US$ 2.51
-0.05 -1.95
142,844
7.26M
US$ 18.220M
US$ 0.57
0.00 0.00
79,759
30.84M
US$ 17.700M
US$ 0.64
-0.03 -4.67
31,652
27.52M
US$ 17.590M
US$ 2.56
0.35 15.84
167,844
6.79M
US$ 17.380M
US$ 0.32
0.00 0.00
0
52.24M
US$ 16.610M
C$ 0.28
-0.005 -1.79
48,679
59.60M
C$ 16.390M
US$ 0.73
-0.06 -8.10
803,715
22.45M
US$ 16.300M
US$ 0.97
0.02 2.65
298,802
16.64M
US$ 16.060M
US$ 10.85
-0.41 -3.64
9,949
1.48M
US$ 16.060M
C$ 0.05
0.00 0.00
0
320.55M
C$ 16.030M
US$ 2.67
0.00 0.00
0
5.89M
US$ 15.730M
US$ 1.15
-0.07 -5.74
207,638
13.30M
US$ 15.290M
US$ 2.04
0.00 0.00
0
7.09M
US$ 14.440M
US$ 0.67
-0.02 -2.90
41,130
20.63M
US$ 13.820M
C$ 0.06
0.00 0.00
4,000
217.73M
C$ 13.060M
US$ 0.18
-0.0053 -2.89
1.32M
72.19M
US$ 12.850M
US$ 0.52
0.04 8.33
12,473
24.39M
US$ 12.680M
US$ 2.11
-0.02 -0.94
284,602
5.89M
US$ 12.430M
US$ 4.77
-0.51 -9.68
37,422
2.46M
US$ 11.730M
US$ 1.10
-0.04 -3.51
376,871
10.63M
US$ 11.690M
US$ 0.61
0.00 0.00
0
19.01M
US$ 11.530M
US$ 0.77
-0.06 -7.23
350,704
14.59M
US$ 11.230M
US$ 5.45
-0.44 -7.47
92,297
2.05M
US$ 11.170M
US$ 0.34
-0.04 -10.26
1.08M
31.90M
US$ 10.880M
US$ 2.26
0.01 0.62
3,215
4.17M
US$ 9.440M
US$ 4.58
0.00 0.00
0
2.04M
US$ 9.340M
US$ 1.91
0.01 0.53
361,817
4.81M
US$ 9.190M
US$ 0.28
-0.02 -5.15
807,882
31.93M
US$ 8.810M
US$ 1.27
0.00 0.00
0
6.24M
US$ 7.920M
C$ 0.08
0.00 0.00
0
100.02M
C$ 7.500M
US$ 1.19
-0.05 -4.03
277,047
6.00M
US$ 7.140M
US$ 0.64
-0.04 -5.96
452,562
11.07M
US$ 7.060M
C$ 0.02
0.005 50.00
423,259
451.63M
C$ 6.770M
US$ 2.48
-0.08 -3.12
111,295
2.71M
US$ 6.720M
US$ 0.96
-0.03 -3.03
99,880
6.67M
US$ 6.400M
C$ 0.06
0.005 10.00
8,000
101.29M
C$ 5.570M
C$ 0.11
0.00 0.00
0
48.23M
C$ 5.060M
C$ 0.04
0.00 0.00
0
122.72M
C$ 4.910M
C$ 0.05
0.00 0.00
0
96.48M
C$ 4.820M
US$ 0.06
0.00 0.00
0
73.90M
US$ 4.510M
US$ 0.66
-2.45 -78.78
183,470
6.63M
US$ 4.380M
US$ 0.74
-0.04 -5.25
34,461
5.85M
US$ 4.330M
US$ 0.28
-0.03 -9.84
1.43M
15.58M
US$ 4.280M
US$ 0.35
0.00 0.00
0
11.88M
US$ 4.160M
US$ 1.83
-0.16 -8.04
123,403
2.22M
US$ 4.060M
US$ 1.02
-0.13 -11.30
1.18M
3.75M
US$ 3.820M
US$ 0.78
0.00 0.00
0
4.85M
US$ 3.780M
US$ 3.57
-0.03 -0.75
20,820
980,321
US$ 3.500M
US$ 0.14
-0.0001 -0.07
100,049
21.04M
US$ 2.950M
US$ 0.35
-0.08 -18.84
21.04M
8.00M
US$ 2.790M
US$ 0.88
-0.06 -6.40
288,104
3.14M
US$ 2.760M
US$ 0.50
0.00 0.00
0
5.24M
US$ 2.610M
US$ 1.41
0.00 0.00
0
1.82M
US$ 2.570M
US$ 1.30
-0.07 -5.11
206,560
1.77M
US$ 2.300M
US$ 0.20
0.00 0.00
0
10.59M
US$ 2.110M
US$ 0.51
-0.09 -15.25
9.11M
3.73M
US$ 1.900M
US$ 3.47
-0.20 -5.46
109,425
536,908
US$ 1.860M
US$ 2.52
-0.59 -18.97
1.24M
729,980
US$ 1.840M
US$ 0.47
0.00 0.00
0
3.20M
US$ 1.520M
US$ 0.08
0.00 0.00
0
16.67M
US$ 1.370M
US$ 0.28
-0.03 -10.28
7.80M
4.37M
US$ 1.230M
US$ 0.01
-0.0001 -0.90
1,007
96.71M
US$ 1.060M
US$ 1.07
-0.06 -5.40
305,761
962,637
US$ 1.030M
US$ 1.66
-0.11 -6.21
108,966
552,854
US$ 918K
US$ 0.03
0.00 0.00
0
25.04M
US$ 851K
US$ 0.10
0.00 0.00
0
7.26M
US$ 697K
US$ 1.15
0.00 0.00
0
418,049
US$ 481K
C$ 0.005
0.00 0.00
0
59.81M
C$ 299K
US$ 0.06
0.00 0.00
0
1.78M
US$ 100K
US$ 0.002
0.0002 11.11
3,273
29.91M
US$ 60K
US$ 0.00
0.00 0.00
0
40.35M
US$ -
US$ 0.00
0.00 0.00
0
15.85M
US$ -
US$ 0.00
0.00 0.00
0
6.39M
US$ -
US$ 0.00
-0.0001 -100.00
94.09M
855.04M
US$ -
C$ 0.36
0.00 0.00
123,000
-
C$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest News From Medical Stocks


Modular Medical to Present Data from Study Examining Pump Delivery of a GLP-1R Agonist at the ADA 85th Scientific Sessions

SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of "almost-pumpers" with its user-friendly and affordable design, is pleased to announce its participation in the American Diabetes Association ("ADA") 85th Scientific Sessions, taking place June 20-23, 2025, at the McCormick Place Convention... Read more


Abbott Receives Health Canada Authorization for Whole Blood Rapid Test to Help Assess Suspected Concussions

The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), otherwise known as concussion The test produces lab-quality results in 15 minutes Clinicians can get a result at the patient's bedside, making the test accessible at urgent care clinics and healthcare settings outside of the hospital emergency room The test can be used to help evaluate patients up to 24 hours... Read more


ENDRA Life Sciences’ Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

Refinements to probe configuration and proprietary algorithms are expected to drive substantial improvements in MRI-PDFF correlation ANN ARBOR, Mich. / Jun 16, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in imaging technologies for the early detection and monitoring of metabolic liver disease, today announced that its ongoing multisite pilot study has helped to identify several product enhancements to further improve the performance of its... Read more


Charles River Laboratories Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

A solution for laboratories seeking to reduce single-use plastic waste WILMINGTON, Mass. / Jun 16, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced a recycling program, developed in partnership with international recycling leader TerraCycle®, to give new life to single-use plastic cartridges. This groundbreaking collaboration offers users of Charles River’s Endosafe® bacterial endotoxin testing (BET) cartridge technology... Read more


Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

LungFit PH II’s smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the country GARDEN CITY, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives... Read more


Helius Medical Technologies Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device

- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160- NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation... Read more


Presenting on Emerging Growth Conference 83 Day 1 on June 17; Register to live stream

MIAMI, June 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 83rd Emerging Growth Conference on June 17 & 18, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions... Read more


908 Devices Appoints Christopher D. Brown to its Board of Directors

BOSTON / Jun 16, 2025 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (Nasdaq: RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company’s Chief Technology Officer & Vice President of Research... Read more


QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples Partnership supports Incyte’s extensive portfolio in... Read more


InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS. CGuard® Prime was developed incorporating extensive user feedback and optimizes deliverability and deployment of the proven CGuard stent. With its proprietary MicroNet™ mesh,... Read more


LevelJump Healthcare to Acquire Two Alberta Diagnostic Imaging Clinics; Update on Year-End Reporting Documents

Toronto, Ontario--(Newsfile Corp. - June 13, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), is pleased to announce that its subsidiary, Canadian Teleradiology Services ("CTS"), has signed a definitive agreement to acquire two diagnostic imaging clinics, also known as independent healthcare facilities ("IHFs"), from private Alberta vendors. The purchase price is $1.92 million cash which includes a $20,000 deposit. The transaction is targeted... Read more


RetinalGenix Technologies Welcomes Dr. Taimour Langaee as Advisor for DNA GPS Pharmacogenetics Initiatives

Appointment Underscores RetinalGenix’s Commitment to Integrating the Latest Advances in Genomics and Personalized Medicine into its Product Pipeline APOLLO BEACH, Fla., June 13, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneer in advanced retinal imaging and precision medicine, is pleased to announce the appointment of Dr. Taimour Langaee, MSPH, PhD, as its newest scientific advisor. Dr. Langaee... Read more


VolitionRx Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care HENDERSON, Nev., June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a new clinical manuscript suggesting that the Nu.Q® H3.1 biomarker has the potential to inform clinical care in critically-ill Intensive Care Unit (ICU) patients in the assessment of sepsis, organ failure and su... Read more


Tempus AI Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research

CHICAGO / Jun 12, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer's disease research. The collaboration leverages Tempus’ AI-powered data... Read more


Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapies PITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services. As part of an ongoing... Read more


Agilent Technologies to Showcase New Products and Innovations at HPLC 2025

SANTA CLARA, Calif. / Jun 12, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that they will introduce their latest Hybrid Multisampler and highlight the new LC Single Quadrupole Mass Spectrometers at the upcoming HPLC 2025 conference in Bruges, Belgium. These new additions are designed to boost laboratory efficiency and deliver superior results. Exhibition attendees will be able to see how these products can streamline operations and enhance analytical... Read more


Tenon Medical Announces Initial Case Series Utilizing Catamaran(R) SI Joint Fusion System to Enhance Stabilization of the SI Joint for Patients Undergoing Lumbar Fusion

Andrew J. Trontis, MD from Progressive Spine and Orthopaedics, (Englewood, NJ) Completes Initial Case Series  LOS GATOS, CA / ACCESS Newswire / June 12, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the completion of an initial case series utilizing the Catamaran® SI Joint Fusion System (the "Catamaran") to immobilize &... Read more


Helius Medical Technologies: Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting

PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis Presentation of full PoNSTEP study results expanded upon top line data previously reported NEWTOWN, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance... Read more


Teleflex: New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients

WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey. Key highlights... Read more


Prenetics Global Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon

Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics) Raises full year revenue outlook to $80 - $100 million (excluding ACT Genomics) IM8 contributed $5.7 million in Q1, with $2.8 million in March alone & provides Q2 revenue projections IM8 has more than 55,000 customers with 4.9 million servings delivered and counting Details of crypto strategy and Bitcoin adoption to be announced soon as part of innovative treasury approach CHARLOTTE,... Read more


Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new data highlighting two oncology radiodiagnostic agents will be presented at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place... Read more


Aspira Women's Health Provides Update on ARPA-H Sprint Program Partnership to Advance Women's Health

AUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / June 11, 2025 / Aspira Women's Health Inc., ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announces an update from the Advanced Research Projects Agency for Health's ( ARPA-H ) Sprint for Women's Health program initiative to address critical unmet needs in women's health. Aspira was... Read more


Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing

SMARTOX has deployed over 50 of INBS’ Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone Company continues to actively pursue FDA clearance in connection with planned expansion into broader U.S. markets in 2025 NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent,... Read more


NanoVibronix: ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System

Patent strengthens ENvue’s IP position as it advances toward pediatric regulatory clearance and expanded clinical use TYLER, Texas / Jun 11, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division (“ENvue Medical” or “ENvue”), a new U.S. patent for its pediatric feeding tube guidance system.... Read more


BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)

Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial BURLINGTON, Mass. and JERUSALEM, June 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced preliminary results from a multicenter, randomized controlled trial titled, “Accelerated Deep TMS for Depression:... Read more


IQVIA Launches New AI Agents for Life Sciences and Healthcare

RESEARCH TRIANGLE PARK, N.C. / Jun 11, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA’s new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic architectures illustrate how IQVIA AI... Read more


Helius Medical Technologies Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic... Read more


MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori),... Read more


Hyperfine Announces Key Executive Appointments to Strengthen its Leadership Position in AI-Powered Portable MRI

Rafael O’Halloran, PhD, and Rob Fasciano, PhD, bring depth and breadth of experience in imaging and Medtech. GUILFORD, Conn. / Jun 11, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced the appointments of Rob Fasciano, PhD, as Chief Regulatory and Quality Officer, and Rafael O’Halloran,... Read more


Perimeter Medical Imaging AI to Present at the Life Sciences Virtual Investor Forum on June 12th

TORONTO and DALLAS, June 10, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that its CEO, Adrian Mendes, will present an update on the Company's business at the Life Sciences Virtual Investor Forum on Thursday, June 12, 2025 at 12:30 p.m. Eastern Time. A live stream of the presentation will be available here and on the Investors... Read more


Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Study is Intended to Verify Previous Discovery Results Demonstrating Sensitivity of 95% and Specificity of 98% BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commencement of the next phase in its PancAlert project, a research initiative focused on developing a non-invasive... Read more


Insulet’s Omnipod 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users

Dexcom G7 sensor integration offers more customers the ability to manage diabetes from their iPhone, for additional convenience ACTON, Mass. / Jun 10, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. With this latest integration, the Omnipod 5 Automated Insulin Delivery... Read more


Envoy Medical's Pivotal Clinical Trial for Fully Implanted Acclaim(R) Cochlear Implant Remains On Track After First Month Follow-Up

Positive momentum from the trial's first stage encouraging Company to accelerate plans for expansion and commercialization White Bear Lake, Minnesota--(Newsfile Corp. - June 10, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that all 10 of the study participants in the first stage of the Company's pivotal clinical... Read more


Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program

NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical innovation and excellence MALVERN. Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, is proud to share two significant updates underscoring... Read more


Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor

SAN DIEGO / Jun 10, 2025 / Business Wire / Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone... Read more


Vivani Medical to Present at the 2025 BIO International Convention

ALAMEDA, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the 2025 BIO International Convention, taking place from June 16-19, 2025 in Boston, Massachusetts. Details around Dr. Mendelsohn’s... Read more


Lantheus to Present at the 2025 Truist Securities MedTech Conference

BEDFORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the 2025 Truist Securities MedTech Conference at 8:40 a.m. ET on Tuesday, June 17. To access a live webcast of the presentation, please visit... Read more


New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia

EEG-Guided Anesthesia Using Masimo Technology Significantly Reduced Pediatric Anesthesia Emergence Delirium, Time to Emergence and Discharge, and Cost of Care by Minimizing Sevoflurane Exposure NEUCHATEL, Switzerland / Jun 10, 2025 / Business Wire / Masimo (NASDAQ: MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women’s Medical University demonstrated the ability of... Read more


Quantum-Si’s Single-Molecule Tech Enables Precise, Multiplexed Measurement of Nanobody Binding in a Single Assay

Researchers at ESPCI Paris and Quantum-Si demonstrate scalable platform for parallel binding kinetics and sequencing in new preprint BRANFORD, Conn. / Jun 10, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, announces a new preprint from researchers at Quantum-Si and ESPCI Paris that introduces a powerful method... Read more


Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology

SECAUCUS, N.J., June 10, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) designed to improve the assessment of elevated risk of cancer in individuals who would benefit from medically appropriate cancer screenings.  Under terms of the agreement, Quest will develop and validate a laboratory-developed blood... Read more


Izotropic Revises License Agreement with The Regents of the University of California

License agreement enables U.S. FDA approval or foreign equivalent (CE mark) Amendment aligns with Company's timelines for IzoView product launch Agreement amendment fees of USD $85K payable in installments  Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing... Read more


Profound Medical Announces First Commercial BPH Patient Treatment Using TULSA-PRO® with TULSA-AI® Volume Reduction

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce that the first commercial benign prostatic hyperplasia (“BPH”) treatment utilizing the TULSA-PRO® system’s new TULSA-AI® Volume Reduction Module was successfully... Read more


Spectral AI DeepView® System highlighted at the annual British Burn Association conference

DALLAS, June 10, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the annual British Burn Association (BBA) conference, held from June 4th – 6th in Brighton, UK. The Company was featured in multiple presentations, highlighting its contributions to... Read more


Nuwellis Announces Closing of $5.0 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

MINNEAPOLIS, June 10, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced the closing of a public offering of 2,580,667 shares of its common stock (“Common Stock”), pre-funded warrants to purchase 14,085,998 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 49,999,995... Read more


Anteris Technologies Appoints David Roberts and Gregory Moss to its Board of Directors

New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts... Read more


Prestige Consumer Healthcare to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference

TARRYTOWN, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference virtually on Wednesday, June 11, 2025 at 10:30 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link:... Read more


Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025

Presentation to be webcast live at 10:00 AM ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced that Robert Hayes, CEO, will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET. Investors are invited to listen... Read more


New medial stabilized insert for Smith+Nephew’s LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatility

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023.1 With the ability to be used with or without the Posterior Cruciate Ligament (PCL), procedural trends are moving away from Posterior Stabilized (PS) design... Read more


Nano-X Imaging to Present at the Investor Summit Virtual on June 10, 2025

PETACH TIKVA, ISRAEL / ACCESS Newswire / June 9, 2025 / Nanox Imaging announced that Ran Daniel, Chief Financial Officer, will be presenting at the Investor Summit Virtual taking place on June 10.About Nanox Imaging Nanox (NASDAQ:NNOX) is focused on driving the world's transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X-ray source. Nanox's vision encompasses expanding... Read more


Electromed to Present at the Investor Summit Virtual on June 10, 2025

NEW PRAGUE, MN / ACCESS Newswire / June 9, 2025 / Electromed, Inc. announced that Jim Cunniff, President and Chief Executive Officer, will be presenting at the Investor Summit Virtual taking place on June 10.About Electromed, Inc. Electromed (NYSE American: ELMD) is a profitable and growing medical device company that develops, manufactures, markets and sells innovative High Frequency Chest Wall Oscillation (HFCWO) airway clearance products, primarily for use in the home... Read more